STAT Plus: Amgen’s KRAS-blocking drug shows small improvement in colon cancer response

Amgen’s experimental KRAS-blocking drug is showing a modest improvement in response rates for patients with advanced colon cancer and other solid tumors — but the new data are unlikely to…